• Carmen Riggioni, Pasquale Comberiati, Mattia Giovannini, Ioana Agache, Mübeccel Akdis, Magna Alves-Correia, Josep M Antó, Alessandra Arcolaci, Ahmet Kursat Azkur, Dilek Azkur, Burcin Beken, Cristina Boccabella, Jean Bousquet, Heimo Breiteneder, Daniela Carvalho, Leticia De Las Vecillas, Zuzana Diamant, Ibon Eguiluz-Gracia, Thomas Eiwegger, Stefanie Eyerich, Wytske Fokkens, Ya-Dong Gao, Farah Hannachi, Sebastian L Johnston, Marek Jutel, Aspasia Karavelia, Ludger Klimek, Beatriz Moya, Kari C Nadeau, Robyn O'Hehir, Liam O'Mahony, Oliver Pfaar, Marek Sanak, Jürgen Schwarze, Milena Sokolowska, María J Torres, Willem van de Veen, Menno C van Zelm, WangDe YunY0000-0002-0909-2963Department of Otolaryngology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore., Luo Zhang, Rodrigo Jiménez-Saiz, and Cezmi A Akdis.
• Pediatric Allergy and Clinical Immunology Department, Hospital Sant Joan de Déu, Barcelona, Spain.
• Allergy. 2020 Oct 1; 75 (10): 2503-2541.

AbstractIn December 2019, China reported the first cases of the coronavirus disease 2019 (COVID-19). This disease, caused by the severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), has developed into a pandemic. To date, it has resulted in ~9 million confirmed cases and caused almost 500 000 related deaths worldwide. Unequivocally, the COVID-19 pandemic is the gravest health and socioeconomic crisis of our time. In this context, numerous questions have emerged in demand of basic scientific information and evidence-based medical advice on SARS-CoV-2 and COVID-19. Although the majority of the patients show a very mild, self-limiting viral respiratory disease, many clinical manifestations in severe patients are unique to COVID-19, such as severe lymphopenia and eosinopenia, extensive pneumonia, a "cytokine storm" leading to acute respiratory distress syndrome, endothelitis, thromboembolic complications, and multiorgan failure. The epidemiologic features of COVID-19 are distinctive and have changed throughout the pandemic. Vaccine and drug development studies and clinical trials are rapidly growing at an unprecedented speed. However, basic and clinical research on COVID-19-related topics should be based on more coordinated high-quality studies. This paper answers pressing questions, formulated by young clinicians and scientists, on SARS-CoV-2, COVID-19, and allergy, focusing on the following topics: virology, immunology, diagnosis, management of patients with allergic disease and asthma, treatment, clinical trials, drug discovery, vaccine development, and epidemiology. A total of 150 questions were answered by experts in the field providing a comprehensive and practical overview of COVID-19 and allergic disease.© 2020 European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.

23 keywords...

hide…